Hepatitis blood tests are a distinct category of liver-related testing that goes beyond the standard liver function panel — they are specific serological and molecular tests designed to identify whether the liver inflammation (hepatitis) a patient has is caused by one of the hepatitis viruses, and if so, which one, at what stage, and whether it requires treatment. While the standard liver function panel (ALT, AST, ALP, GGT, bilirubin, albumin) tells us whether the liver is injured and how severely, hepatitis blood tests tell us why — specifically whether a viral infection is the cause. Understanding which hepatitis tests are used, what each result means, and how to interpret combinations of serology (antibody) and molecular (viral genetic material) results is essential for anyone managing patients with liver disease or trying to understand a diagnosis of viral hepatitis.
The hepatitis viruses most relevant in clinical practice in the United States are hepatitis A (HAV), hepatitis B (HBV), and hepatitis C (HCV). Hepatitis D (HDV) is a defective virus that only infects people already infected with hepatitis B — it requires the HBV surface antigen to replicate and is therefore only relevant in the context of HBV co-infection or superinfection. Hepatitis E (HEV) is a waterborne virus that is the leading cause of acute viral hepatitis globally — it is most clinically significant in pregnant women (where it causes severe disease) and in immunocompromised individuals in developed countries, where zoonotic transmission from pigs produces a genotype 3 infection that can become chronic. Each of these viruses uses different routes of transmission, has different natural histories, and requires different specific tests for diagnosis and monitoring — which is why “hepatitis testing” is not a single test but a family of tests that must be selected according to the clinical question being asked.
Hepatitis A Testing
Hepatitis A virus (HAV) causes acute self-limiting hepatitis transmitted primarily through the fecal-oral route — contaminated food and water, close contact with infected individuals, and travel to endemic regions. In the United States, hepatitis A is increasingly seen in outbreaks among people experiencing homelessness and people who inject drugs. The key hepatitis A serological tests are:
Anti-HAV IgM — the antibody that appears within one to two weeks of acute HAV infection and remains positive for three to six months. A positive anti-HAV IgM in a patient with acute hepatitis (elevated ALT, jaundice, symptoms) confirms acute hepatitis A infection and requires notification to public health authorities in most jurisdictions. Anti-HAV IgG (total anti-HAV) — the long-term antibody that appears during the acute illness and persists lifelong, conferring immunity. Positive anti-HAV IgG with negative anti-HAV IgM indicates past infection or vaccination — not active disease. Testing for total anti-HAV (IgG) before hepatitis A vaccination is used in some clinical settings to check whether the patient is already immune and does not require vaccination. Hepatitis A does not become chronic — after resolution of the acute illness (which may take weeks to months for liver enzymes to normalise), HAV is cleared from the body and lifelong immunity follows. Treatment of acute hepatitis A is supportive (rest, hydration, avoidance of hepatotoxic drugs and alcohol, fomite precautions). For context on the clinical presentation of acute hepatitis A, the article on jaundice and what it signals about liver injury provides useful background.
Hepatitis B Testing — Serology and Viral Load
Hepatitis B testing is the most complex of the viral hepatitis serological panels, because HBV infection involves multiple antigens (surface, e, core) and their corresponding antibodies, each providing different information about the stage of infection, immune response, replication status, and treatment eligibility. The core hepatitis B tests are:
HBsAg (Hepatitis B surface antigen) — the first marker to appear after HBV infection (two to four weeks before ALT elevation), and the defining marker of active HBV infection. Positive HBsAg indicates current HBV infection — either acute (if the patient is within the first six months of infection) or chronic (if positive for more than six months). All patients with newly detected HBsAg positivity should have HBV DNA viral load, HBeAg/anti-HBe, liver function tests, abdominal ultrasound, and assessment for cirrhosis. Anti-HBs (antibody to HBsAg) — appears after resolution of acute HBV infection or after successful vaccination, conferring immunity. Isolated anti-HBs positivity with negative HBsAg and negative anti-HBc indicates vaccine-induced immunity. Anti-HBc IgM — the antibody to the hepatitis B core antigen, IgM class. Positive anti-HBc IgM indicates recent acute HBV infection (within three to six months) — it is the key marker for diagnosing acute hepatitis B when HBsAg may have already cleared (the serological window period). Anti-HBc total (IgG) — persists lifelong after resolved HBV infection, indicating past exposure. Isolated anti-HBc positivity (HBsAg negative, anti-HBs negative, anti-HBc positive) is an important pattern that may indicate resolved infection, past infection with waned surface antibody, or occult HBV — where the virus persists at very low levels without detectable HBsAg — and warrants HBV DNA testing to clarify. HBeAg / anti-HBe — the e antigen indicates active viral replication; its presence alongside HBsAg (HBeAg-positive chronic hepatitis B) indicates a high viral load phase associated with greater infectivity and liver inflammation. Anti-HBe appears when the immune system achieves e antigen seroconversion, typically marking a reduction in viral replication. HBV DNA (viral load) — the direct quantitative measure of HBV genetic material in blood, measured in IU/mL. HBV DNA determines treatment eligibility, monitors antiviral therapy response, and assesses for drug resistance. International guidelines (AASLD, EASL) use HBV DNA thresholds alongside ALT level, immune phase, and fibrosis stage to determine when antiviral therapy should be initiated. Achieving and maintaining undetectable viral load on treatment is the primary endpoint of hepatitis B antiviral therapy, even though it does not constitute cure (HBsAg remains positive).
Hepatitis C Testing — Antibody, RNA, and Genotype
Hepatitis C testing in current clinical practice follows a two-step cascade recommended by the CDC and WHO: first, a screening test (anti-HCV antibody), then confirmation with a molecular test (HCV RNA) if the antibody is positive. This two-step approach reflects the biology of HCV infection: anti-HCV antibody appears two to twelve weeks after infection and persists lifelong — even after the virus is cleared — so a positive anti-HCV alone cannot distinguish between active infection, resolved past infection, and false positive. Only HCV RNA positivity confirms active (current) HCV replication. The practical pathway is: positive anti-HCV antibody → HCV RNA test → if RNA positive, active infection confirmed; if RNA negative, past resolved infection (or rarely, early infection before viraemia is detectable).
Anti-HCV (antibody) — the screening test, positive from approximately two to twelve weeks after infection and lifelong thereafter. Sensitivity exceeds ninety-nine percent in immunocompetent individuals after the window period. False positives occur (particularly with older EIA-based assays) and false negatives can occur within the first weeks of infection and in severely immunocompromised patients. HCV RNA (viral load) — detectable within one to two weeks of infection, before antibody. Positive HCV RNA confirms active viremia and is required to start treatment. HCV RNA quantification is measured before and during treatment to confirm treatment response. HCV genotype — HCV has eight major genotypes (1–8), with genotypes 1, 2, and 3 predominating in the United States. Genotyping was essential for determining treatment regimen and duration in the era of interferon-based therapy; most modern pan-genotypic direct-acting antivirals (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) work across all genotypes without genotyping, though some regimens remain genotype-specific. Genotype 3 is associated with faster fibrosis progression and higher hepatocellular carcinoma risk. Sustained virological response (SVR) — undetectable HCV RNA twelve weeks after completing antiviral treatment — is the definition of virological cure. SVR rates exceed ninety-five percent with current pan-genotypic DAA regimens. After SVR, HCV RNA monitoring is used to confirm durability of response. The article on fatigue as the most common symptom of chronic hepatitis C provides context on the clinical experience of HCV infection before and after treatment.
Frequently Asked Questions About Hepatitis Blood Tests
I tested positive for hepatitis C antibody — does that mean I have hepatitis C?
A positive anti-HCV antibody means you have been exposed to the hepatitis C virus at some point in your life — it does not necessarily mean you currently have an active infection. Approximately twenty to thirty percent of people who are infected with hepatitis C spontaneously clear the virus during the acute phase of infection (usually within six months), after which the antibody remains positive for life but there is no active viral replication. The only way to know whether you currently have hepatitis C is to test for HCV RNA (viral load) — if HCV RNA is detectable, you have active hepatitis C requiring treatment; if HCV RNA is undetectable, you have resolved or cleared hepatitis C and do not require antiviral therapy. The current CDC recommendation is that all adults age eighteen and older should be screened for hepatitis C at least once in their lifetime — so a positive antibody result, while requiring follow-up RNA testing, is not automatically cause for alarm. Understanding the combination of liver synthetic function markers and viral hepatitis tests together gives the most complete picture of how much liver damage, if any, the infection has caused.
What does it mean to be a hepatitis B “carrier”?
The term “carrier” is an older, somewhat imprecise term that has been largely replaced in clinical practice by more specific descriptions of hepatitis B immune phases. Traditionally, “carrier” referred to individuals with chronic HBV infection (HBsAg positive for more than six months) who were HBeAg-negative with low or undetectable viral load and normal liver enzymes — the “inactive carrier” or “inactive chronic HBV” phase, representing immune control of the virus. These individuals have low levels of viral replication and generally minimal liver inflammation, but they retain a lifelong risk of viral reactivation (particularly with immunosuppressive therapy), and a residual long-term risk of hepatocellular carcinoma even in the absence of cirrhosis, particularly in patients of Asian heritage and those with cirrhosis from prior immune clearance activity. “Active” HBV infection — with detectable viral load, elevated ALT, and ongoing liver inflammation — is the phase that most strongly drives fibrosis progression and requires treatment. All individuals with chronic hepatitis B — regardless of their phase — require lifelong monitoring with six-monthly ALT, HBV DNA, and hepatocellular carcinoma surveillance ultrasound and AFP. The clinical management of HBV connects to the article on warning signs of advancing liver disease that should trigger earlier clinical assessment.
Sources: CDC — Viral Hepatitis · AASLD — Hepatitis Guidelines · WHO — Hepatitis C Fact Sheet
Hepatitis D and E Testing
Hepatitis D virus (HDV) is a satellite virus that can only replicate in the presence of hepatitis B surface antigen — it requires the HBV surface antigen envelope to package its own RNA and infect new cells. HDV infection therefore only occurs in two scenarios: simultaneous co-infection (acquiring HDV and HBV at the same time, usually through intravenous drug use or unprotected sex with an HBV/HDV co-infected individual) and superinfection (acquiring HDV in a person who already has chronic HBV). HDV superinfection is clinically more severe: it typically causes a flare of hepatitis in a previously stable chronic HBV carrier and carries a risk of accelerated fibrosis progression to cirrhosis that is substantially higher than HBV alone. The diagnostic tests are: anti-HDV antibody (screening — positive indicates exposure, but does not distinguish active from past infection) and HDV RNA by polymerase chain reaction (PCR) — the definitive marker of active HDV replication. In all patients with chronic hepatitis B, particularly those with unexplained hepatitis flares, accelerated cirrhosis progression, or from high HDV-endemic regions (Mongolia, Central Asia, Eastern Europe, parts of Africa and South America), HDV testing should be performed. Bulevirtide — the first specifically approved HDV antiviral — received European approval in 2020 and has shown significant reduction in HDV RNA and liver inflammation in Phase 3 trials, representing the first meaningful treatment advance for this infection in decades.
Hepatitis E virus (HEV) is the most common cause of acute viral hepatitis globally, transmitted primarily through contaminated water in endemic regions (genotypes 1 and 2, predominantly in Asia, Africa, and Central America) and through undercooked pork and other animal products in developed countries (genotype 3, which is zoonotic and can also be acquired through blood transfusion). In immunocompetent individuals, HEV infection is typically self-limiting — causing an acute hepatitis lasting two to six weeks that resolves without specific treatment. However, two groups require particular attention: pregnant women in the third trimester, in whom HEV genotype 1 infection carries a case fatality rate of ten to twenty-five percent from fulminant hepatic failure; and immunocompromised patients (organ transplant recipients, haematological malignancy, HIV with low CD4 count), in whom HEV genotype 3 can establish chronic infection, progressing to cirrhosis within a few years if untreated. HEV testing includes anti-HEV IgM (acute infection marker, positive for two to three months), anti-HEV IgG (past infection or vaccination marker, persists longer), and HEV RNA PCR (definitive confirmation of active viraemia, required in immunocompromised patients where antibody responses may be blunted). HEV RNA testing is particularly important in organ transplant recipients presenting with unexplained elevated ALT, as serological tests may be negative in this population due to impaired antibody production under immunosuppression.
HBV Reactivation — Testing in Immunosuppressed Patients
Hepatitis B reactivation — the resurgence of HBV replication in individuals with resolved (anti-HBc positive, HBsAg negative) or chronic occult HBV infection following immunosuppressive therapy — is one of the most important hepatitis testing considerations in clinical practice, because it can produce severe hepatitis and acute liver failure if not anticipated and prevented. Rituximab (anti-CD20 therapy for lymphomas and autoimmune diseases), high-dose corticosteroids, cancer chemotherapy, biological agents (TNF-alpha inhibitors, anti-interleukin therapies), and haematopoietic stem cell transplantation all carry significant risk of HBV reactivation in HBsAg-positive or anti-HBc-positive patients. The AASLD and AST (American Society of Transplantation) guidelines recommend universal hepatitis B screening (HBsAg and anti-HBc at minimum) before initiating any significantly immunosuppressive therapy, with pre-emptive antiviral prophylaxis (entecavir or tenofovir) for high-risk patients. This screening also extends to all patients with HIV, haematological malignancies, solid organ transplant recipients, and patients receiving anti-rejection medications — populations in whom undetected chronic or resolved HBV is a frequently encountered clinical challenge. The article on liver function tests explained provides the broader framework for monitoring liver health during and after these immunosuppressive treatments.
Post-treatment monitoring after completing hepatitis C direct-acting antiviral therapy provides another important application of hepatitis blood tests. After eight to twelve weeks of DAA treatment, a sustained virological response (SVR) is confirmed by undetectable HCV RNA twelve weeks after the last dose. Patients who achieve SVR are virologically cured of hepatitis C — the virus does not persist as a latent infection (unlike HBV), and re-infection only occurs through renewed exposure. However, liver disease monitoring continues after SVR for patients with pre-treatment advanced fibrosis or cirrhosis: these individuals retain elevated risk of hepatocellular carcinoma despite viral cure (HCC risk is substantially reduced but not eliminated by SVR in cirrhotic patients), and six-monthly HCC surveillance with ultrasound and AFP should continue indefinitely. For patients with pre-cirrhotic disease at SVR, the risk of HCC is low enough that surveillance is not routinely recommended, though liver stiffness monitoring (FibroScan) to confirm fibrosis regression over subsequent years is a common clinical practice. The connection between hepatitis treatment success and the reduction of the visible symptoms of liver disease — including those covered in the article on itching from cholestatic liver disease — demonstrates how viral clearance translates to clinical and quality-of-life improvement.
Autoimmune Hepatitis and Non-Viral Hepatitis Testing
When the hepatitis blood tests for HAV, HBV, and HCV return negative in a patient with elevated liver enzymes and hepatitis-pattern liver injury, the investigation expands to include non-viral causes of hepatitis — particularly autoimmune hepatitis (AIH). Autoimmune hepatitis is an immune-mediated inflammatory liver disease that predominantly affects women (three to four times more commonly than men), can present at any age, and produces a hepatocellular pattern of liver injury (elevated ALT and AST, variable bilirubin) that is indistinguishable on biochemistry alone from viral hepatitis. The diagnostic tests for autoimmune hepatitis include: anti-nuclear antibody (ANA) — positive in approximately seventy to eighty percent of AIH Type 1; anti-smooth muscle antibody (ASMA) — positive in approximately seventy percent of AIH Type 1, where it is more specific than ANA; anti-liver kidney microsomal type 1 antibody (anti-LKM-1) — the defining marker of AIH Type 2, more common in children and young adults; anti-soluble liver antigen (anti-SLA) — high specificity for AIH when positive; serum immunoglobulin G (IgG) — elevated in the majority of AIH cases, often to more than twice the upper limit of normal. The combination of these markers, hepatitis viral serology negativity, liver histology (interface hepatitis, plasma cell infiltration), and clinical context allows AIH diagnosis using the International Autoimmune Hepatitis Group (IAIHG) simplified criteria. First-line treatment with prednisolone and azathioprine achieves remission in eighty to ninety percent of patients within twelve months — making timely diagnosis directly therapeutically important.
The complete evaluation of elevated liver enzymes in the absence of positive hepatitis viral serology should systematically include: Wilson’s disease (caeruloplasmin, urinary copper, slit-lamp examination — particularly in patients under thirty-five), alpha-1 antitrypsin deficiency (alpha-1 antitrypsin level and phenotyping — a not-uncommonly missed genetic cause of liver disease presenting in young adults), haemochromatosis (ferritin, transferrin saturation, HFE gene testing), and drug-induced liver injury (comprehensive medication and supplement history). This non-viral hepatitis differential is important because each of these conditions has specific treatment: copper chelation for Wilson’s, antioxidant and lifestyle management for haemochromatosis, alpha-1 antitrypsin augmentation therapy for deficiency, and immunosuppression for autoimmune hepatitis. Missing the diagnosis because viral serology was the only testing performed represents a preventable diagnostic delay with potential implications for long-term liver health. Understanding how the full picture of liver tests — including the role of ALT, AST, bilirubin, albumin, and specialist tests — fits together is the foundation of accurate liver disease diagnosis, and the article on ALT and AST blood tests provides the detailed aminotransferase framework that underlies this diagnostic approach.
Hepatitis blood testing represents one of the most impactful areas of preventive medicine and communicable disease control in hepatology: identifying undiagnosed HBV and HCV infections, enabling vaccination of susceptible individuals, facilitating antiviral treatment that prevents cirrhosis and liver cancer, and monitoring treatment responses that determine long-term outcomes. The CDC universal screening recommendation for HCV in all adults, the WHO global hepatitis elimination targets for 2030, and national HBV birth dose vaccination programmes all depend on the accurate use and interpretation of these blood tests at the individual patient level. Whether you are receiving results for the first time, monitoring a known hepatitis infection, or being screened before immunosuppressive therapy, understanding what each hepatitis blood test marker means — and what follow-up action is required — is the foundation of informed hepatitis care.
I tested positive for hepatitis C antibody two years ago and was told to ‘come back for follow-up’ but the follow-up never happened. After reading this I now understand I needed an HCV RNA test to know if I actually have active hepatitis C. I’m booking an appointment to get that test done. Thank you for making this so clear.
Michelle, please do follow up — you are absolutely right that a positive anti-HCV antibody test is not the end of the story, it’s the beginning. HCV RNA testing is the critical next step. If HCV RNA comes back detectable, the good news is that current hepatitis C treatment (8–12 weeks of oral direct-acting antivirals) cures over 95% of cases. Two years is not too long to have waited — treatment is just as effective now as it would have been then. Ask your GP specifically for an HCV RNA test by name.
The section on HBV reactivation screening before immunosuppressive therapy is something that should be required reading for every rheumatologist and oncologist. The number of preventable cases of HBV reactivation from rituximab or high-dose steroids in patients with unrecognised resolved HBV infection is still higher than it should be.